- Standort
-
Deutsche Nationalbibliothek Frankfurt am Main
- Umfang
-
1 Online-Ressource.
- Sprache
-
Englisch
- Erschienen in
-
Divarasib in the Evolving Landscape of KRAS G12C Inhibitors for NSCLC ; volume:19 ; number:3 ; day:13 ; month:5 ; year:2024 ; pages:297-301 ; date:5.2024
Targeted oncology ; 19, Heft 3 (13.5.2024), 297-301, 5.2024
- Urheber
-
Brazel, Danielle
Nagasaka, Misako
- Beteiligte Personen und Organisationen
-
SpringerLink (Online service)
- DOI
-
10.1007/s11523-024-01055-y
- URN
-
urn:nbn:de:101:1-2408011334100.598822478671
- Rechteinformation
-
Open Access; Der Zugriff auf das Objekt ist unbeschränkt möglich.
- Letzte Aktualisierung
- 14.08.2025, 10:47 MESZ
Datenpartner
Dieses Objekt wird bereitgestellt von:
Deutsche Nationalbibliothek. Bei Fragen zum Objekt wenden Sie sich bitte an den Datenpartner.
Deutsche Nationalbibliothek. Bei Fragen zum Objekt wenden Sie sich bitte an den Datenpartner.
Beteiligte
- Brazel, Danielle
- Nagasaka, Misako
- SpringerLink (Online service)
Ähnliche Objekte (12)
Wee1 inhibitor MK1775 sensitizes KRAS mutated NSCLC cells to sorafenib
Ancestry-associated co-alteration landscape of KRAS and EGFR-altered non-squamous NSCLC
The current landscape of using direct inhibitors to target KRASG12C-mutated NSCLC
MAPPING EVOLVING HISTORICAL LANDSCAPE SYSTEMS
Chronic Kidney Disease and SGLT2 Inhibitors: A Review of the Evolving Treatment Landscape
Spatial iTME analysis of KRAS mutant NSCLC and immunotherapy outcome
The energetic and allosteric landscape for KRAS inhibition
The Evolving Landscape of Myelodysplastic Syndrome Prognostication
Gastric cancer: current and evolving treatment landscape
The Evolving Treatment Landscape of Medullary Thyroid Cancer
The evolving therapeutic landscape of genetic skeletal disorders
The Rapidly Evolving Landscape of DCD Heart Transplantation
Wee1 inhibitor MK1775 sensitizes KRAS mutated NSCLC cells to sorafenib
Ancestry-associated co-alteration landscape of KRAS and EGFR-altered non-squamous NSCLC
The current landscape of using direct inhibitors to target KRASG12C-mutated NSCLC
MAPPING EVOLVING HISTORICAL LANDSCAPE SYSTEMS
Chronic Kidney Disease and SGLT2 Inhibitors: A Review of the Evolving Treatment Landscape
Spatial iTME analysis of KRAS mutant NSCLC and immunotherapy outcome
The energetic and allosteric landscape for KRAS inhibition
The Evolving Landscape of Myelodysplastic Syndrome Prognostication
Gastric cancer: current and evolving treatment landscape
The Evolving Treatment Landscape of Medullary Thyroid Cancer
The evolving therapeutic landscape of genetic skeletal disorders
The Rapidly Evolving Landscape of DCD Heart Transplantation
Wee1 inhibitor MK1775 sensitizes KRAS mutated NSCLC cells to sorafenib
Ancestry-associated co-alteration landscape of KRAS and EGFR-altered non-squamous NSCLC
The current landscape of using direct inhibitors to target KRASG12C-mutated NSCLC
MAPPING EVOLVING HISTORICAL LANDSCAPE SYSTEMS
Chronic Kidney Disease and SGLT2 Inhibitors: A Review of the Evolving Treatment Landscape
Spatial iTME analysis of KRAS mutant NSCLC and immunotherapy outcome
The energetic and allosteric landscape for KRAS inhibition
The Evolving Landscape of Myelodysplastic Syndrome Prognostication
Gastric cancer: current and evolving treatment landscape
The Evolving Treatment Landscape of Medullary Thyroid Cancer
The evolving therapeutic landscape of genetic skeletal disorders